Clinical characteristics of infant neuroblastoma and a summary of treatment outcome

Zhang, Yi; Huang, Dongsheng; Zhang, Weiling; Tang, Suo-Qin; Han, Tao; Zhu, Xiaozhong; Liu, Aiping; Zhi, Tian

doi:10.3892/ol.2016.5353

Cited by 9 publications

(5 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In France, as in other countries, age less than 1 year at diagnosis is a very poor prognostic factor for leukemia and CNS tumors, and a good prognostic factor for neuroblastoma [3,19]. The good prognosis of infantile neuroblastoma has been attributed to the fact that patients aged less than 1 year have smaller and less aggressive tumors (less metastatic and less MYCN-amplified diseases), which, in some cases, regress spontaneously [20][21][22]. There are a higher proportion of MYCN-amplified tumors in infants with stage 4 disease compared to those without metastatic neuroblastoma (19% vs. 3%) [23,24].…”

Section: Discussionmentioning

confidence: 99%

Infant cancers in France: Incidence and survival (2000–2014)

Désandes

Guissou

Berger

et al. 2020

Cancer Epidemiology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Infant cancers in France: Incidence and survival (2000–2014)

Désandes

Guissou

Berger

et al. 2020

Cancer Epidemiology

View full text Add to dashboard Cite

“…The clinical expression of NB is highly varied: in some patients, the tumour may regress spontaneously while in others it progresses despite intense multimodal therapy ( 5 ). The metastatic disease in infants, the so-called stage MS (4S according to the INSS), represents 7–10% of all NB cases ( 11 ). It is a unique, neuroblastoma-specific stage, which, despite its massive metastasising to the liver, skin, and bone marrow, is usually characterised by a low risk and a good prognosis.…”

Section: Discussionmentioning

confidence: 99%

Results of neuroblastoma treatment in Lithuania: a single centre experience

Juskaite¹,

Tamulienė²,

Rascon³

2017

AML

View full text Add to dashboard Cite

Background.Neuroblastoma (NB) is the most common extracranial solid tumour in children. This is a very rare disease with heterogeneous biology varying from complete spontaneous regression to a highly aggressive tumour responsible for 15% of malignancy-related death in early childhood. Analyses of survival rates in Europe have shown a considerable difference between Northern/Western and Eastern European countries. Treatment results of NB in Lithuania have never been analyzed.Aim.To assess the survival rate of children with NB according to initial spread of the disease, age at diagnosis, the MYCN amplification, risk group, and treatment period.Patients and methods.A retrospective single-centre analysis of patients’ records was performed. Children diagnosed and treated for NB between 2000 and 2015 at the Centre of Paediatric Oncology and Haematology of the Children’s Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos were included. The patients were divided into three groups according to the spread of the disease: group 1 – patients with local NB older than 12 years of age; group 2 – stage IV patients, also called the M stage; group 3 – infants with stages 4S and MS. The patients were stratified into three risk groups – low, intermediate and high risk. Estimates of five-year overall survival (OS5y) were calculated using the Kaplan-Meier method comparing survival probability according to spread of the disease, age at diagnosis, the MYCN amplification, risk group and treatment period (2000–2007 vs 2008–2015).Results.Overall 60 children (31 girls and 29 boys) with NB were included. The median age at diagnosis was 1.87 years (ranged from 4 days to 15 years). Seventy-eight percent of cases were found to be differentiated or undifferentiated NB, 22% – ganglioneuroblastoma. The local form of the disease was predominant: 57% (34/60) of patients were allocated to the group 1, 37% (22/60) with initial metastatic disease were assigned to group 2, and infants with 4S or MS stage comprising 7% (4/60) allocated to group 3, respectively. The probability of OS5y for the entire cohort was 71% with the median follow-up of 8.8 ± 4.8 years. The probability of OS5y for local disease (group 1) was significantly higher compared to metastatic disease (group 2) (94% vs. 34%, p = 0.001, respectively) as well as for infants compared to children older than 12 months at the time of diagnosis (90% vs 60%, p = 0.009, respectively). The MYCN gene amplification had a negative influence on OS5y, with 78% of MYCN-negative patients surviving in comparison to 40% of MYCN-positive patients who did not survive (p = 0.153). The high-risk patients had significantly worse OS5y than children with intermediated or low risk (35% vs. 82% vs. 100%, respectively, p = 0.001). Comparison of OS5y between two treatment periods in the entire patient population revealed a non-significant increase in survival from 66% in the 2000–2007 period to 82% in the 2008–2015 period (p = 0.291), mostly due to a dramatic improvement achieved for high-risk patients...

show abstract

“…Long noncoding RNA-NBAT-1 (NB-Associated Transcript 1) were found to epigenetically downregulate the tumorigenic factors and promote differentiation of NB tumor cells [81]. The involvement of long non-coding RNAs (lncRNAs), alternative splicing programs, fragile sites and genome-wide methylation has been emphasizing the importance of the developmental context of NB (Figure 2), [60,[81][82][83].…”

Section: Molecular Pathogenesismentioning

confidence: 99%

Mini-review: Current challenges in the treatment of developmentally diverse neuroendocrine like tumors: Comparison of bronchial carcinoids and neuroblastoma

Morgatskaya¹,

Yeger²,

Talukdar³

et al. 2019

View full text Add to dashboard Cite

Bronchial carcinoids (BC) derive from the pulmonary neuroendocrine cell system while neuroblastoma (NB) derives from the neural crest and represents the peripheral nervous system. Nevertheless, their production of serotonin and catecholamines, respectively, permits comparison as neuroendocrine tumors (NETs). BC are most often diagnosed in adults accounting for 1-5% of all invasive lung malignancies in the adults. NB, primarily a pediatric cancer, accounts for 7-8% of all childhood cancers with the highest incidence in children younger than 5 years, and frequent metastasis to liver, skin, bone, and brain. The major standard treatments for BC is surgery followed by endocrine therapy and chemotherapies. NB patients on the other hand receive treatments according to presenting stage with chemotherapies dominant and now newer immunotherapies at more advanced stages. In general BC are more indolent but when less differentiated can be aggressive portending a poorer outcome. NB in contrast often present at an advanced stage and if high stage the overall survival approaches 25% despite extensive and other therapies. Early stage diagnosis still remains a challenge since symptomology depends on their neuroendocrine manifestation. Here we summarize the current knowledge and challenges in the management of BC and NB.

show abstract

Clinical characteristics of infant neuroblastoma and a summary of treatment outcome

Cited by 9 publications

References 35 publications

Infant cancers in France: Incidence and survival (2000–2014)

Infant cancers in France: Incidence and survival (2000–2014)

Results of neuroblastoma treatment in Lithuania: a single centre experience

Mini-review: Current challenges in the treatment of developmentally diverse neuroendocrine like tumors: Comparison of bronchial carcinoids and neuroblastoma

Contact Info

Product

Resources

About